You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

concurrent chemoradiotherpay

Showing 26 - 50 of 2,089
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Long Term Efficacy and Safety Trial (Imlifidase administered in the 20-HMedIdeS-19 (PAES) study, Best available treatment

Not yet recruiting
  • Long Term Efficacy and Safety
  • Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
  • Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
  • (no location specified)
Jun 30, 2023

Esophageal Squamous Cell Carcinoma Trial in Nanjing (Carrelizumab, Paclitaxel injection, Cisplatin)

Enrolling by invitation
  • Esophageal Squamous Cell Carcinoma
  • Nanjing, China
    The First Affiliated Hospital of Nanjing Medical University
Sep 19, 2023

Head and Neck Tumors Trial in Nanjing (Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU)

Recruiting
  • Head and Neck Tumors
  • Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU
  • Nanjing, Jiangsu, China
    Department of Oncology, Drum Tower Hospital, Nanjing University
Feb 24, 2023

Epilepsy Trial in Phoenix, Boston (Tripolar electroencephalography)

Not yet recruiting
  • Epilepsy
  • Tripolar electroencephalography
  • Phoenix, Arizona
  • +1 more
Jul 6, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou, Zhongshan, Nanning (IMRT and concurrent cisplatin, gemcitabine and cisplatin

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • IMRT and concurrent cisplatin
  • gemcitabine and cisplatin (Induction chemotherapy)
  • Guangzhou, Guangdong, China
  • +3 more
Jul 30, 2023

Locally Advanced NSCLC, Efficacy and Safety Trial in Guangzhou (Anlotinib, Chemotherapy, Radiotherapy)

Recruiting
  • Locally Advanced Non-small Cell Lung Cancer
  • Efficacy and Safety
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Jul 28, 2022

Esophageal Cancer Trial (Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B), Adjuvant chemoradiotherapy)

Not yet recruiting
  • Esophageal Cancer
  • Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)
  • Adjuvant chemoradiotherapy
  • (no location specified)
Dec 19, 2022

Rectal Cancer Trial in Shanghai (dosimetric limitation of pelvic bone and peritoneal space during radiotherapy)

Active, not recruiting
  • Rectal Cancer
  • dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jan 8, 2023

Capecitabine With Adjuvant Radiotherapy in Treatment of Early

Not yet recruiting
  • Breast Cancer
  • Radiotherapy
  • (no location specified)
Jan 30, 2023

Nasopharyngeal Carcinoma, De-escalation Therapy Trial in Guangzhou (Cisplatin-based induction chemo, Full course of PD-1/PD-L1

Recruiting
  • Nasopharyngeal Carcinoma
  • De-escalation Therapy
  • Cisplatin-based induction chemotherapy
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 16, 2023

To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced

Not yet recruiting
  • To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
  • Hydrochloride anlotinib
  • +2 more
  • (no location specified)
Mar 6, 2023

Measures for Pain in Multiple Sclerosis

Not yet recruiting
  • Pain
    • (no location specified)
    Feb 14, 2023

    Gastrointestinal Cancer Trial in Bani Suwayf (oral nutrition supplement)

    Recruiting
    • Gastrointestinal Cancer
    • oral nutrition supplement
    • BanÄ« Suwayf, Egypt
      Beni suef university hospital
    Aug 4, 2023

    Osteosarcoma Trial in Shanghai (metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic

    Recruiting
    • Osteosarcoma
    • metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University, School of Medici
    Nov 1, 2023

    NSCLC Trial in Worldwide (MEDI4736, PLACEBO)

    Active, not recruiting
    Has Results
    • Non-Small Cell Lung Cancer
    • Chandler, Arizona
    • +235 more
    Jan 4, 2023

    Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Trial (Radiotherapy, Toripalimab)

    Not yet recruiting
    • Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
    • (no location specified)
    Mar 17, 2023

    Solid Tumors, Cancer Trial in Worldwide (MEDI1191, Durvalumab)

    Active, not recruiting
    • Solid Tumors
    • Cancer
    • MEDI1191
    • Durvalumab
    • La Jolla, California
    • +13 more
    Nov 30, 2022

    Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone Trial in Shanghai (Camrelizumab and fluzoparib with concurrent stereotactic body

    Recruiting
    • Sarcoma
    • +2 more
    • Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University, School of Medici
    Oct 3, 2023

    Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III Trial in Tampa (Genomically

    Recruiting
    • Nonsmall Cell Lung Cancer
    • +3 more
    • Genomically Guided Radiation Therapy (RT)
    • Tampa, Florida
      Moffitt Cancer Center
    May 23, 2023

    Locally Advanced Head and Neck Squamous Cell Carcinoma Trial in Worldwide (volrustomig)

    Not yet recruiting
    • Locally Advanced Head and Neck Squamous Cell Carcinoma
    • Prescott Valley, Arizona
    • +71 more
    Nov 10, 2023

    Rectal Cancer Trial in Kaohsiung (for excise, nutrition consultant, nutrition supplement and psychologic intervention.)

    Not yet recruiting
    • Rectal Cancer
    • for excise, nutrition consultant, nutrition supplement and psychologic intervention.
    • Kaohsiung, Taiwan
      Chang Gung Memorial Hospital
    Dec 27, 2022

    Tobacco Use Disorder, Alcohol Use Disorder, Smoking Cessation Trial (Cytisine, Placebo)

    Not yet recruiting
    • Tobacco Use Disorder
    • +2 more
    • (no location specified)
    Feb 6, 2023

    Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

    Not yet recruiting
    • Muscle-Invasive Bladder Carcinoma
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Aug 3, 2023

    Invasive Mechanical Ventilation ARDS Trial in Beijing

    Recruiting
    • Invasive Mechanical Ventilation ARDS
      • Beijing, Beijing, China
        Department of Pulmonary and Critical Care Medicine, Chinese PLA
      Jun 27, 2023

      Locally Advanced Rectal Cancer Trial in Beijing (Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor), Long-course

      Recruiting
      • Locally Advanced Rectal Cancer
      • Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)
      • Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)
      • Beijing, Beijing, China
        Beijing Friendship Hospital, Capital Medical University
      Apr 25, 2023